These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33442873)

  • 21. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
    ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.
    Allen JE; Krigsfeld G; Mayes PA; Patel L; Dicker DT; Patel AS; Dolloff NG; Messaris E; Scata KA; Wang W; Zhou JY; Wu GS; El-Deiry WS
    Sci Transl Med; 2013 Feb; 5(171):171ra17. PubMed ID: 23390247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. c-MYC inhibition impairs hypoxia response in glioblastoma multiforme.
    Mongiardi MP; Savino M; Falchetti ML; Illi B; Bozzo F; Valle C; Helmer-Citterich M; Ferrè F; Nasi S; Levi A
    Oncotarget; 2016 May; 7(22):33257-71. PubMed ID: 27119353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microfluidic-Derived Docosahexaenoic Acid Liposomes for Targeting Glioblastoma and Its Inflammatory Microenvironment.
    Mendanha D; Casanova MR; Gimondi S; Ferreira H; Neves NM
    ACS Appl Mater Interfaces; 2024 Aug; 16(31):40543-40554. PubMed ID: 39042828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/macrophages and monocyte-derived macrophages.
    Choi J; Stradmann-Bellinghausen B; Yakubov E; Savaskan NE; Régnier-Vigouroux A
    Cancer Biol Ther; 2015; 16(8):1205-13. PubMed ID: 26047211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
    Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.
    He Y; Li J; Koga T; Ma J; Dhawan S; Suzuki Y; Furnari F; Prabhu VV; Allen JE; Chen CC
    Neuro Oncol; 2021 Mar; 23(3):400-411. PubMed ID: 32830856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
    Allen JE; Crowder RN; El-Deiry WS
    PLoS One; 2015; 10(11):e0143082. PubMed ID: 26580220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
    Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
    J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.
    Ranjan A; Wright S; Srivastava SK
    Oncotarget; 2017 Jul; 8(29):47632-47641. PubMed ID: 28512255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
    Allen JE; Prabhu VV; Talekar M; van den Heuvel AP; Lim B; Dicker DT; Fritz JL; Beck A; El-Deiry WS
    Cancer Res; 2015 Apr; 75(8):1668-74. PubMed ID: 25681273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondria and cancer chemoresistance.
    Guerra F; Arbini AA; Moro L
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
    Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma.
    Maier JP; Ravi VM; Kueckelhaus J; Behringer SP; Garrelfs N; Will P; Sun N; von Ehr J; Goeldner JM; Pfeifer D; Follo M; Hannibal L; Walch AK; Hofmann UG; Beck J; Heiland DH; Schnell O; Joseph K
    Cell Death Dis; 2021 Jul; 12(8):723. PubMed ID: 34290229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.